RT Journal Article
SR Electronic
T1 Protocol of HOTFy: randomised clinical trial to hyperbaric oxygen therapy in fibromyalgia
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e069153
DO 10.1136/bmjopen-2022-069153
VO 13
IS 1
A1 Mota Neto, José
A1 Mendes, Adriano Fernando
A1 Martins, Anita Fernanda Magalhães
A1 Landa, Aline Teixeira de
A1 Fraga, Rafael de Oliveira
A1 Souza, Viviane Angelina de
A1 Raposo, Nádia Rezende Barbosa
YR 2023
UL http://bmjopen.bmj.com/content/13/1/e069153.abstract
AB Introduction Fibromyalgia is a polysymptomatic syndrome with a prevalence between 0.2% and 13% of the population and causes work disabilities in approximately half of affected patients. Several treatments to fibromyalgia have been proposed with partial improvement. This study aims to evaluate the efficacy of hyperbaric oxygen therapy and when it should be introduced to fibromyalgia.Methods and analysis This is a protocol for an open-label, crossover, randomised clinical trial comparing treatment with hyperbaric oxygen therapy and standardised treatment to fibromyalgia. In the proposed study, 56 individuals with fibromyalgia will be randomised in a 1:1 ratio into a single, fixed, random block, in which one group will receive hyperbaric oxygen therapy and another will receive standard treatment. Subsequently, the groups will be crossed. Participants will be evaluated at baseline, eight and 16 weeks based on functional impairment assessed with the Fibromyalgia Impact Questionnaire—Brazilian Portuguese version, psychopathological symptoms questionnaire and short-form quality of life questionnaire. The improvement of symptoms concerning the moment of therapy used will be compared between groups. For sample size calculation, a moderate effect size, 80% power and 95% CI will be estimated, in a total of 46 patients. Considering a dropout of 20%, 56 patients should be recruited.Ethics and dissemination The study was approved by the Universidade Federal de Juiz de Fora Teaching Hospital ethics committee and assigned the number 53058421.9.0000.5133 (version 3). The results will be disseminated via publications in peer-reviewed journals and presentations in medical meetings.Trial registration number RBR-6prps8g)/UTN U1111-1278-3224.